Equity Overview
Price & Market Data
Price: $3.29
Daily Change: -$0.19 / 5.78%
Daily Range: $3.27 - $3.50
Market Cap: $27,439,308
Daily Volume: 12,054
Performance Metrics
1 Week: 3.13%
1 Month: -21.29%
3 Months: -37.45%
6 Months: 11.53%
1 Year: 23.68%
YTD: -31.03%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country:
Details
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.